Bliss Gvs Pharma Limited (BLISSGVS) AI Stock Analysis

• Market Cap: ₹23.66B
• Dividend Yield: 0.28%
• Average Volume (3M): 104.36K
• Price to Earnings (P/E): 18.6
• Beta (1Y): 1.41
• Revenue Growth: 7.51%
• EPS Growth: 71.81%
• Country: IN
• Employees: 831
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.20
• Shares Outstanding: 105,788,970
• 10 Day Avg. Volume: 77,644
• 30 Day Avg. Volume: 104,358
• PEG Ratio: 1.37
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 1.56
• P/FCF Ratio: 42.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: ₹250.00 ▲(72.71% Upside)
• Action: Reiterated Date: 01/07/26
• Date: Action: Reiterated 01/07/26

The score is driven primarily by solid financial fundamentals—especially a strong, low-leverage balance sheet and improving profitability—supported by a clear technical uptrend. Valuation is reasonable on earnings but offers limited support from a very low dividend yield.

Positive Factors

Strong balance sheet

Bliss GVS’s high equity ratio and low leverage provide durable financial flexibility. Low debt reduces refinancing risk and supports working capital for export tenders and manufacturing scale. This stability enables measured capital allocation and resilience to sector cycles over 2–6 months.

Negative Factors

Mixed free cash flow performance

Variable free cash flow and inconsistent FCF growth limit the firm’s ability to consistently fund capex, pay dividends or accelerate deleveraging without external financing. Persistent cash conversion variability could constrain strategic investments or flexibility over the next several quarters.

Bliss Gvs Pharma Limited Business Overview & Revenue Model

Company Description

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear ...

Read more

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear ...

How the Company Makes Money

Bliss GVS Pharma makes money primarily by selling pharmaceutical products. Its key revenue streams include (1) sales of finished dosage formulations (e.g., tablets and other formulations) under its own marketing and distribution channels, (2) expo...

Read more

Bliss GVS Pharma makes money primarily by selling pharmaceutical products. Its key revenue streams include (1) sales of finished dosage formulations (e.g., tablets and other formulations) under its own marketing and distribution channels, (2) expo...

Bliss Gvs Pharma Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.60B	8.10B	7.66B	7.47B	7.38B	5.69B
Gross Profit	3.95B	3.96B	2.49B	3.50B	3.47B	2.40B
EBITDA	2.07B	1.27B	1.49B	1.35B	762.37M	1.27B
Net Income	1.10B	842.99M	754.54M	708.59M	150.40M	684.91M
Balance Sheet
Total Assets	14.00B	13.01B	12.14B	11.57B	11.09B	10.77B
Cash, Cash Equivalents and Short-Term Investments	2.01B	1.41B	1.41B	684.11M	1.35B	616.64M
Total Debt	524.91M	881.04M	998.40M	1.02B	1.09B	1.22B
Total Liabilities	2.32B	2.09B	2.11B	2.39B	2.62B	2.49B
Stockholders Equity	11.32B	10.50B	9.67B	8.84B	8.19B	8.08B
Cash Flow
Free Cash Flow	483.04M	298.48M	1.24B	-594.86M	614.77M	548.45M
Operating Cash Flow	775.52M	1.06B	1.52B	343.13M	1.35B	639.69M
Investing Cash Flow	-272.20M	-754.41M	-1.33B	-77.51M	-929.75M	-469.91M
Financing Cash Flow	-448.06M	-303.45M	-208.93M	-249.38M	-237.30M	-207.98M

Bliss Gvs Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 144.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 144.75 is below the 20-day moving average (MA) of 211.79, below the 50-day MA of 198.45, and below the 200-day MA of 167.81, indicating a bullish trend. The MACD of 1.87 indicates Positive momentum. The RSI at 57.66 is Neutral, neither overbought nor oversold. The STOCH value of 44.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.

Bliss Gvs Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLISSGVS	74 Outperform	₹23.66B	18.57	―	0.28%	7.51%	71.81%
WINDLAS	71 Outperform	₹16.51B	27.93	―	0.71%	19.34%	9.32%
JAGSNPHARM	67 Neutral	₹12.34B	28.83	―	1.24%	24.60%	153.56%
SYNCOMF	64 Neutral	₹10.87B	17.72	―	―	56.41%	90.24%
HESTERBIO	61 Neutral	₹11.75B	38.81	―	0.44%	-3.84%	86.82%
BAJAJHCARE	53 Neutral	₹9.90B	20.91	―	0.24%	13.04%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bliss Gvs Pharma Limited Corporate Events